1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-radiometal complex (DOTA-radiometal complex) (DOTA-radiometal complex)

A DOTA-radiometal complex is a chemical assembly comprising the macrocyclic chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and a radioactive metal ion [1]. This complex is not a biological target but rather a critical component of radiopharmaceuticals used in nuclear medicine for imaging and therapy [2]. DOTA is highly valued for its ability to form exceptionally stable complexes with various trivalent metal ions, such as Gallium-68 for PET imaging or Lutetium-177 and Actinium-225 for radionuclide therapy [3]. These complexes are typically linked to a targeting moiety, such as a peptide or monoclonal antibody, which directs the radioactivity to specific biomarkers like somatostatin receptors or prostate-specific membrane antigen [4]. Once localized at the disease site, the radiometal undergoes decay, emitting particles that either allow for non-invasive visualization or cause lethal DNA damage to malignant cells [5]. The high kinetic stability of the DOTA-metal bond is vital to prevent the release of free, toxic radiometals into non-target tissues like the bone or liver [6]. Consequently, while DOTA-radiometal complexes are therapeutic agents, their clinical success depends on the biological target they are engineered to seek out [7].

Other names

DOTA-radionuclide complexDOTA-chelated metalDOTA-metal complexTetraxetan-metal complexDOTA-radioisotope complex

Chelation and stabilization of radioactive metal isotopes to facilitate their delivery to specific biological sites for diagnostic imaging or targeted radiotherapy [2, 6].